Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 5/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30357138 | 1.00 | TERT (0.65) | TERTMAPK1MAPTGAAALOX15 | |
| SCHEMBL1669 | 0.93 | TERT (0.64) | TERTMAPTMEN1KMT2ANPC1 | |
| SCHEMBL1443 | 0.89 | TERT (0.60) | TERTMAPTGAANPC1RAB9A | |
| SCHEMBL742 | 0.89 | TERT (0.51) | TERTMAPK1MAPTGAAALOX15 | |
| SCHEMBL3670031 | 0.88 | TERT (0.63) | TERTMAPTNPC1RAB9ALMNA | |
| SCHEMBL988 | 0.87 | MAPT (0.50) | TERTMAPK1MAPTGAAALOX15 | |
| SCHEMBL8055429 | 0.86 | TERT (0.56) | TERTMAPTMEN1KMT2ANPC1 | |
| SCHEMBL7960724 | 0.85 | TERT (0.65) | TERTMAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL8125815 | 0.83 | TERT (0.62) | TERTMAPK1MAPTKMT2ANPC1 | |
| SCHEMBL8067045 | 0.83 | TERT (0.52) | TERTMAPTMEN1KMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1077214-A1 | An improved process for preparing a pyrazolopyrimidinone derivative | Orchid Chemicals & Pharmaceuticals Ltd. (IN) | 2001-02-21 | — | — | EP | claimed |
| CN-112209879-A | Sildenafil impurity and preparation method and application thereof | 河北省药品医疗器械检验研究院 | 2021-01-12 | — | — | CN | disclosed |
| CN-111116591-A | Method for preparing sildenafil citrate | 天津科伦药物研究有限公司 | 2020-05-08 | — | — | CN | disclosed |
| US-9663439-B2 | Aildenafil citrate crystal form O, preparation method and use thereof | HONG KONG GOLDEN WISDOM MEDICAL PRODUCTION LIMITED (HK) | 2017-05-30 | — | — | US | disclosed |
| US-9663439-B2 | Aildenafil citrate crystal form O, preparation method and use thereof | HONG KONG GOLDEN WISDOM MEDICAL PRODUCTION LIMITED (HK) | 2017-05-30 | — | — | US | disclosed |
| US-20130165448-A1 | AILDENAFIL CITRATE CRYSTAL FORM O, PREPARATION METHOD AND USE THEREOF | HONG KONG GOLDEN WISDOM MEDICAL PRODUCTION LIMITED (HK) | 2013-06-27 | — | — | US | disclosed |
| US-20130165448-A1 | AILDENAFIL CITRATE CRYSTAL FORM O, PREPARATION METHOD AND USE THEREOF | HONG KONG GOLDEN WISDOM MEDICAL PRODUCTION LIMITED (HK) | 2013-06-27 | — | — | US | disclosed |
| US-8071765-B2 | Process for the preparation of sildenafil and intermediates thereof | TOPHARMAN SHANGHAI CO., LTD. (CN) | 2011-12-06 | — | — | US | disclosed |
| US-8071765-B2 | Process for the preparation of sildenafil and intermediates thereof | TOPHARMAN SHANGHAI CO., LTD. (CN) | 2011-12-06 | — | — | US | disclosed |
| EP-2125821-B1 | PROCESS FOR THE PREPARATION OF SILDENAFIL | KRKA TOVARNA ZDRAVIL D D NOVO MESTO (SI) | 2011-07-13 | — | — | EP | disclosed |
| EP-1002798-A1 | An improved process for preparing a therapeutically active pyrazolopyrimidinone derivative | Orchid Chemicals & Pharmaceuticals Ltd. (IN) | 2000-05-24 | — | — | EP | disclosed |
| US-5719283-A | INHIBITORS OF PHOSPHODIESTERASES; CARDIOVASCULAR DISORDERS | PFIZER INC. (US) | 1998-02-17 | — | — | US | disclosed |
| EP-0526004-B1 | Pyrazolopyrimidinone antianginal agents | PFIZER LTD (GB) | 1997-10-08 | — | — | EP | disclosed |
| US-5426107-A | Treatment of cardiovascular disorders, asthma, allergies | PFIZER INC. (US) | 1995-06-20 | — | — | US | disclosed |
| EP-0463756-B1 | Pyrazolopyrimidinone antianginal agents | PFIZER LTD (GB) | 1995-04-19 | — | — | EP | disclosed |
| US-5346901-A | Treatment of angina, hypertension, heart failure and atherosclerosis | PFIZER INC. (US) | 1994-09-13 | — | — | US | disclosed |
| US-5272147-A | Pyrazolopyrimidinone antianginal agents | PFIZER INC. (US) | 1993-12-21 | — | — | US | disclosed |
| US-5250534-A | Inhibitors of cyclic guanosine 3*,5*-monophosphate phosphodiesterase | PFIZER INC. (US) | 1993-10-05 | — | — | US | disclosed |
| EP-0526004-A1 | Pyrazolopyrimidinone antianginal agents | Pfizer Limited (GB) | 1993-02-03 | — | — | EP | disclosed |
| EP-0463756-A1 | Pyrazolopyrimidinone antianginal agents | Pfizer Limited (GB) | 1992-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165448-A1 | AILDENAFIL CITRATE CRYSTAL FORM O, PREPARATION METHOD AND USE THEREOF | PDE5A, PDE3A, PDE3B | TERT 3952/4885MAPK1 2206/4885MAPT 1746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.